The Effect of Cytisine Treatment for Smoking Cessation on Cardiovascular Function in Adult Smokers
Recruiting
Observational Study
Smoking Cessation
Arterial Stiffness
Endothelial Dysfunction
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Observational
- Participants needed
- 200 (estimated)
- Sponsor
- University of Athens · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Introduction: Pharmacological interventions can enhance smoking cessation success and long-term abstinence. Cytisine, a plant derived alkaloid, is a selective partial agonist at alpha-4 beta-2 nicotinic acetylcholine receptors, which are crucial in nicotine dependence.
Aim of the Study The primary objective of this observational study is to evaluate the efficacy of cytisine in a standard 25-day d…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Smokers willing to participate
Exclusion Criteria:
* history of coronary artery disease, active malignancy, history of severe liver and renal failure, history of autoimmune disease.
Contacts